Circadian Rhythm Interventions for Binge Eating Disorder
(CHRONO-BE Trial)
Trial Summary
What is the purpose of this trial?
This trial tests if exposing patients with Binge Eating Disorder to morning light and giving them a Melatonin pill can help reset their body clock and reduce binge eating. Melatonin is a hormone involved in appetite regulation and food intake, and its supplementation has been studied for its potential to restore balance in cases of circadian disruption. The study focuses on obese adults aged 18-50.
Will I have to stop taking my current medications?
You may need to stop taking certain medications that affect the circadian system, like B-blockers, hypnotic sedatives, anticoagulants, antidiabetes drugs, oral corticosteroids, and other immunosuppressants. If you are on these medications, you should discuss with the trial team to see if adjustments are needed.
What data supports the effectiveness of the treatment for Binge Eating Disorder?
Is bright light therapy safe for humans?
How does the circadian rhythm intervention treatment differ from other treatments for binge eating disorder?
This treatment is unique because it focuses on regulating the body's natural 24-hour cycle (circadian rhythm) to address binge eating disorder, using methods like bright light exposure to improve mood and eating patterns. Unlike traditional treatments that may focus solely on behavior or nutrition, this approach targets the underlying biological rhythms that can contribute to disordered eating.12367
Research Team
Francisco Romo-Nava, MD, PhD
Principal Investigator
University of Cincinnati/ Lindner Center of HOPE
Eligibility Criteria
This trial is for adults aged 18-50 with a BMI of ≥30 kg/m2 and diagnosed with moderate to severe Binge Eating Disorder (BED) as per DSM-5 criteria. Participants should not be on any new BED medication or have started psychotherapy within the last 2 or 3 months, respectively. Other moderate psychiatric conditions are allowed if stable, and effective contraception must be used by those who can bear children.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Observational Phase
Circadian system function is evaluated in 80 adult obese subjects, 40 with BED and 40 without BED as a control group.
Treatment
A 4-week double-blinded, randomized, sham/placebo controlled study to evaluate the effect of morning lights and Melatonin/placebo on the circadian system and eating behavior.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Melatonin (Other)
- Morning light version 1 (Behavioural Intervention)
- Morning light version 2 (Behavioural Intervention)
- Placebo (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Cincinnati
Lead Sponsor
Dr. Greg Postel
University of Cincinnati
Chief Medical Officer since 2020
MD from Indiana University School of Medicine
Dr. Neville G. Pinto
University of Cincinnati
Chief Executive Officer since 2017
PhD in Chemistry from the University of Virginia
National Institute of Mental Health (NIMH)
Collaborator
Dr. Joshua A. Gordon
National Institute of Mental Health (NIMH)
Chief Executive Officer since 2016
MD, PhD
Dr. Shelli Avenevoli
National Institute of Mental Health (NIMH)
Chief Medical Officer
PhD
Lindner Center of HOPE
Collaborator